189.97
+3.82(+2.05%)
Currency In USD
| Previous Close | 186.15 |
| Open | 185.87 |
| Day High | 199.49 |
| Day Low | 180.93 |
| 52-Week High | 206.71 |
| 52-Week Low | 26.7 |
| Volume | 846,534 |
| Average Volume | 965,609 |
| Market Cap | 4.02B |
| PE | -14.65 |
| EPS | -12.97 |
| Moving Average 50 Days | 141.09 |
| Moving Average 200 Days | 67.96 |
| Change | 3.82 |
If you invested $1000 in Praxis Precision Medicines, Inc. (PRAX) since IPO date, it would be worth $455.56 as of December 04, 2025 at a share price of $189.97. Whereas If you bought $1000 worth of Praxis Precision Medicines, Inc. (PRAX) shares 3 years ago, it would be worth $5,918.07 as of December 04, 2025 at a share price of $189.97.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Praxis Precision Medicines Announces Positive Results from EMBOLD Study for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies
GlobeNewswire Inc.
12 minutes ago
Successful interim analysis triggered early stop for efficacy Topline study results to be shared at the American Epilepsy Society Annual Meeting on December 6, 2025 Praxis confirms an upcoming meeting with the FDA to discuss the results and NDA pat
Praxis Precision Medicines Announces Positive Pre-NDA Meeting with FDA for Ulixacaltamide in Essential Tremor
GlobeNewswire Inc.
21 minutes ago
Praxis confirms plans to submit the essential tremor NDA for ulixacaltamide in early 2026BOSTON, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insig
Praxis to present latest preclinical and clinical advancements across leading epilepsy portfolio at the 2025 American Epilepsy Society (AES) Annual Meeting
GlobeNewswire Inc.
Nov 24, 2025 9:01 PM GMT
BOSTON, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into therapies for central nervous system (CNS) disorders driven by neuronal excitati